The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis |
- 0.75 ACPE Pharmacy
- 0.75 AMA PRA Category 1 Credit™
- 0.75 ANCC
- 0.75 Participation
|
Enduring |
|
$0.00 |
Dietary Strategies for Reversing Type 2 Diabetes: Advances, Perspectives, and Expert Discussions |
|
Enduring |
|
$0.00 |
At the Forefront of Care for Patients with Worsening Heart Failure: New and Emerging Treatment Options |
- 1.25 ACPE Pharmacy
- 1.25 AMA PRA Category 1 Credit™
- 1.25 ANCC
- 1.25 Participation
|
Enduring |
|
$0.00 |
Addressing the Cardiometabolic Risk Continuum in MASH: What Clinicians Need to Know |
- 1.00 CDE
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Participation
|
Enduring |
|
$0.00 |
Clinical Brief: Advancements in Dyslipidemia Treatments and ASCVD Risk Reduction for High-Risk Individuals |
- 0.50 CDE
- 0.50 ACPE Pharmacy
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC
- 0.50 Participation
|
Enduring |
|
$0.00 |
Navigating Cardiorenal Metabolic Complexities: A Case Study of a 64-Year-Old Female with T2D, HTN, CKD, and Obesity |
- 0.50 CDE
- 0.50 ACPE Pharmacy
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC
- 0.50 Participation
|
Enduring |
|
$0.00 |